1.35
前日終値:
$1.29
開ける:
$1.4
24時間の取引高:
1.55M
Relative Volume:
0.75
時価総額:
$155.70M
収益:
$13.45M
当期純損益:
$-178.23M
株価収益率:
-0.8182
EPS:
-1.65
ネットキャッシュフロー:
$-132.53M
1週間 パフォーマンス:
-18.18%
1か月 パフォーマンス:
+7.14%
6か月 パフォーマンス:
+5.47%
1年 パフォーマンス:
-43.04%
Fate Therapeutics Inc Stock (FATE) Company Profile
名前
Fate Therapeutics Inc
セクター
電話
858.875.1803
住所
12278 SCRIPPS SUMMIT DRIVE, SAN DIEGO, CA
FATE を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
|
FATE
Fate Therapeutics Inc
|
1.35 | 148.78M | 13.45M | -178.23M | -132.53M | -1.65 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.57 | 107.66B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
651.80 | 68.74B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.04 | 58.93B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
818.50 | 50.51B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.60 | 41.29B | 447.02M | -1.18B | -868.57M | -6.1812 |
Fate Therapeutics Inc Stock (FATE) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-10-31 | アップグレード | H.C. Wainwright | Neutral → Buy |
| 2025-10-27 | アップグレード | Wedbush | Neutral → Outperform |
| 2024-11-18 | アップグレード | BofA Securities | Underperform → Neutral |
| 2024-06-17 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2023-03-27 | 再開されました | Wells Fargo | Equal Weight |
| 2023-01-24 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2023-01-06 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
| 2023-01-06 | ダウングレード | BofA Securities | Buy → Underperform |
| 2023-01-06 | ダウングレード | Cowen | Outperform → Market Perform |
| 2023-01-06 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2023-01-06 | ダウングレード | Stifel | Buy → Hold |
| 2023-01-06 | ダウングレード | Truist | Buy → Hold |
| 2023-01-06 | ダウングレード | Wedbush | Outperform → Neutral |
| 2023-01-03 | ダウングレード | Guggenheim | Buy → Neutral |
| 2022-12-22 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2022-12-15 | 開始されました | Goldman | Sell |
| 2022-11-04 | 再開されました | Cantor Fitzgerald | Overweight |
| 2022-10-10 | 開始されました | Canaccord Genuity | Buy |
| 2022-08-18 | 再開されました | Wells Fargo | Overweight |
| 2022-07-28 | 開始されました | Needham | Hold |
| 2022-07-11 | アップグレード | BMO Capital Markets | Market Perform → Outperform |
| 2022-06-03 | 開始されました | Robert W. Baird | Neutral |
| 2022-02-11 | 再開されました | BMO Capital Markets | Market Perform |
| 2021-12-15 | アップグレード | Wedbush | Neutral → Outperform |
| 2021-12-07 | 開始されました | Cowen | Outperform |
| 2021-11-09 | アップグレード | Citigroup | Neutral → Buy |
| 2021-08-26 | 開始されました | Morgan Stanley | Equal-Weight |
| 2021-06-07 | アップグレード | H.C. Wainwright | Neutral → Buy |
| 2021-05-07 | アップグレード | Wedbush | Neutral → Outperform |
| 2021-04-26 | 再開されました | Jefferies | Buy |
| 2021-02-26 | 開始されました | BofA Securities | Buy |
| 2021-02-26 | ダウングレード | Wedbush | Outperform → Neutral |
| 2021-02-11 | ダウングレード | Citigroup | Buy → Neutral |
| 2021-01-27 | 再開されました | H.C. Wainwright | Neutral |
| 2020-05-13 | 開始されました | H.C. Wainwright | Buy |
| 2020-03-04 | 開始されました | Barclays | Overweight |
| 2020-01-09 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
| 2019-12-30 | 繰り返されました | Mizuho | Buy |
| 2019-12-09 | アップグレード | Wells Fargo | Market Perform → Outperform |
| 2019-11-12 | 開始されました | SunTrust | Buy |
| 2019-11-06 | ダウングレード | Wells Fargo | Outperform → Market Perform |
| 2019-10-01 | 開始されました | Stifel | Buy |
| 2019-08-09 | 開始されました | BTIG Research | Buy |
| 2019-07-22 | 開始されました | Cantor Fitzgerald | Overweight |
| 2019-07-12 | 開始されました | Oppenheimer | Outperform |
| 2019-06-13 | 開始されました | Mizuho | Buy |
| 2019-06-07 | 開始されました | ROTH Capital | Neutral |
| 2019-05-31 | 開始されました | Guggenheim | Buy |
| 2019-05-24 | 再開されました | Citigroup | Buy |
| 2019-03-28 | 開始されました | SVB Leerink | Outperform |
| 2019-01-03 | ダウングレード | Stephens | Overweight → Equal-Weight |
| 2018-11-05 | 開始されました | Jefferies | Buy |
| 2018-08-01 | 開始されました | Citigroup | Buy |
| 2018-03-06 | ダウングレード | H.C. Wainwright | Buy → Neutral |
すべてを表示
Fate Therapeutics Inc (FATE) 最新ニュース
Will Fate Therapeutics Inc. stock recover faster than marketAnalyst Upgrade & Smart Investment Allocation Insights - newser.com
Can trapped investors hope for a rebound in Fate Therapeutics Inc.Volume Spike & Fast Exit Strategy with Risk Control - newser.com
Is Fate Therapeutics Inc. stock undervalued vs historical averagesSell Signal & Free Safe Entry Trade Signal Reports - newser.com
What Fibonacci levels say about Fate Therapeutics Inc. reboundWeekly Stock Analysis & AI Optimized Trading Strategy Guides - newser.com
Will Fate Therapeutics Inc. see short term momentumMarket Movers & AI Driven Stock Reports - newser.com
How sentiment analysis helps forecast Fate Therapeutics Inc.2025 EndofYear Setup & Expert Verified Movement Alerts - newser.com
How Fate Therapeutics Inc. stock benefits from global expansionEntry Point & Free Verified High Yield Trade Plans - newser.com
Why Fate Therapeutics Inc. stock is a value investor pickJuly 2025 Gainers & Precise Buy Zone Identification - newser.com
Why Fate Therapeutics Inc. stock remains a top recommendation2025 Short Interest & Growth Focused Entry Point Reports - newser.com
Fate Therapeutics Shares Rise After HC Wainwright Upgrade - MarketScreener
HC Wainwright & Co. Upgrades Fate Therapeutics (FATE) - Nasdaq
HC Wainwright Upgrades Fate Therapeutics to Buy From Neutral, $5 Price Target - MarketScreener
Developing predictive dashboards with Fate Therapeutics Inc. dataMarket Growth Review & Capital Protection Trading Alerts - newser.com
How to use a screener to detect Fate Therapeutics Inc. breakoutsJuly 2025 PostEarnings & Technical Confirmation Alerts - newser.com
Multi factor analysis applied to Fate Therapeutics Inc.2025 Market WrapUp & Expert Approved Trade Ideas - newser.com
Q3 Earnings Forecast for Fate Therapeutics Issued By Wedbush - MarketBeat
What drives Fate Therapeutics Inc stock priceVolume Weighted Average Price & Low Cost Trading Plans - earlytimes.in
Analyzing drawdowns of Fate Therapeutics Inc. with statistical tools2025 Big Picture & Entry Point Confirmation Signals - newser.com
Fate Therapeutics Reports Promising Phase 1 Trial Results - MSN
Is Fate Therapeutics Inc. stock resilient to inflation2025 Short Interest & Accurate Entry and Exit Point Alerts - Fundação Cultural do Pará
Automated trading signals detected on Fate Therapeutics Inc.Weekly Profit Summary & Risk Managed Investment Entry Signals - newser.com
Fate Therapeutics Forms Golden Cross, Signaling Potential Bullish Breakout Ahead - Markets Mojo
Risk Analysis: Is Fate Therapeutics Inc. stock undervalued vs historical averagesJuly 2025 Drop Watch & Safe Investment Capital Preservation Plans - fcp.pa.gov.br
Fate Therapeutics’ Phase 1 Study: A Potential Game-Changer in Autoimmune Disease Treatment - TipRanks
Fate Therapeutics Inc (FATE) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):